Debt-free Balance SheetElimination of debt in FY2025 materially improves financial flexibility and lowers solvency risk for a biotech with ongoing R&D needs. A debt-free structure reduces interest burden and lengthens runway, enabling strategic optionality such as partnerships or continued investment without immediate refinancing pressure.

Very High Gross Margins And Positive Net IncomeA ~97% gross margin paired with return to net profitability (¥113M) indicates strong unit economics and potential for scalable margins as revenue stabilizes. Durable high gross margins provide a structural cushion against cost volatility and support future operating leverage as commercial traction improves.

Improving Capital Efficiency And Equity BufferPositive ROE (~6.6%) and a sizable equity base signal improving capital efficiency and a meaningful equity buffer. This supports funding of operations and R&D internally to an extent, reducing immediate reliance on dilutive financing and enabling medium-term investment in growth or strategic partnerships.

Bears Say

Persistent Negative Cash FlowConsistently negative operating and free cash flow demonstrates the company remains cash-burning despite accounting profitability. This structural cash outflow forces dependence on external financing or partnerships to fund operations and trials, raising dilution and runway risk over the medium term.

Weak Operating Profitability And Declining RevenueA YoY revenue decline alongside negative EBIT indicates core operations have not achieved sustainable profitability. Net income improvement may reflect non-operating items; without stabilizing top-line growth and converting EBIT positive, margin durability and genuine earnings quality remain uncertain.

Limited Operational Scale And Execution RiskA very small employee base and a history of negative ROE suggest limited internal capacity to scale R&D, commercialization, and regulatory processes. Execution will likely rely on external partnerships or hires, increasing operational risk and the time needed to translate margins into sustained revenue growth.

4889 FAQ

What was Renascience Inc.’s price range in the past 12 months?

Renascience Inc. lowest stock price was ¥868.00 and its highest was ¥3310.00 in the past 12 months.

What is Renascience Inc.’s market cap?

Renascience Inc.’s market cap is ¥25.23B.

When is Renascience Inc.’s upcoming earnings report date?

Renascience Inc.’s upcoming earnings report date is May 07, 2026 which is in 61 days.

How were Renascience Inc.’s earnings last quarter?

Renascience Inc. released its earnings results on Feb 13, 2026. The company reported -¥5.21 earnings per share for the quarter, missing the consensus estimate of N/A by -¥5.21.

Is Renascience Inc. overvalued?

According to Wall Street analysts Renascience Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renascience Inc. pay dividends?

Renascience Inc. does not currently pay dividends.

What is Renascience Inc.’s EPS estimate?

Renascience Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renascience Inc. have?

Renascience Inc. has 13,250,100 shares outstanding.

What happened to Renascience Inc.’s price movement after its last earnings report?

Renascience Inc. reported an EPS of -¥5.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.626%.

Which hedge fund is a major shareholder of Renascience Inc.?

Currently, no hedge funds are holding shares in JP:4889

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renascience Inc.

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.